A Novel Assay to Trace Proliferation History In Vivo Reveals that Enhanced Divisional Kinetics Accompany Loss of Hematopoietic Stem Cell Self-Renewal by Nygren, Jens M. & Bryder, David
A Novel Assay to Trace Proliferation History In Vivo
Reveals that Enhanced Divisional Kinetics Accompany
Loss of Hematopoietic Stem Cell Self-Renewal
Jens M. Nygren*, David Bryder
Stem Cell Aging, Department of Experimental Medical Science, Lund University, Lund, Sweden
Abstract
Background: The maintenance of lifelong blood cell production ultimately rests on rare hematopoietic stem cells (HSCs)
that reside in the bone marrow microenvironment. HSCs are traditionally viewed as mitotically quiescent relative to their
committed progeny. However, traditional techniques for assessing proliferation activity in vivo, such as measurement of
BrdU uptake, are incompatible with preservation of cellular viability. Previous studies of HSC proliferation kinetics in vivo
have therefore precluded direct functional evaluation of multi-potency and self-renewal, the hallmark properties of HSCs.
Methodology/Principal Findings: We developed a non-invasive labeling technique that allowed us to identify and isolate
candidate HSCs and early hematopoietic progenitor cells based on their differential in vivo proliferation kinetics. Such cells
were functionally evaluated for their abilities to multi-lineage reconstitute myeloablated hosts.
Conclusions: Although at least a few HSC divisions per se did not influence HSC function, enhanced kinetics of divisional
activity in steady state preceded the phenotypic changes that accompanied loss of HSC self-renewal. Therefore, mitotic
quiescence of HSCs, relative to their committed progeny, is key to maintain the unique functional and molecular properties
of HSCs.
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Introduction
The generation of blood cells is a hierarchical developmental
process that emanates from rare hematopoietic stem cells (HSCs) that
reside in the bone marrow [1]. Previous studies have demonstrated
that HSCs proliferate in vivo with slow kinetics [2,3,4]. Upon
differentiation, HSCs irreversibly enter progenitor cell stages
characterized by extensive proliferation at the expense of their self-
renewal potential [5]. Although this generic model has been relatively
undisputed, mechanisms must exist that allow for modulation of the
proliferative properties of HSC. For example, HSC numbers expand
dramatically following transplantation and it is well established that
cytostatic regimens and cytokines can induce their rapid cycling [6,7].
Furthermore, HSCs proliferate to a higher extent in fetal
development [8] through what appears to be an intrinsic control
mechanism [9]. Defining the mechanisms that govern these events is
of great interest; such information could be used for therapeutic
benefit as well as to increase the current understanding of HSC self-
renewal in both normal and aberrant hematopoiesis.
In an attempt to overcome obstacles associated with traditional
techniques aimed at investigating HSC proliferation dynamics, we
have developed a technique that permits the evaluation of HSC
proliferation in vivo over extended time periods. Intravenous
injection of an N-hydroxysulfosuccinimide biotin derivative (re-
ferred to hereafter as biotin) effectively labeled the membrane
proteins of all hematopoietic cells in peripheral blood, spleen,
thymus, and bone marrow. Upon proliferation, labeled membrane
proteins were distributed roughly equally among daughter cells,
causing a linear reduction in biotin label. The technique therefore
allowedforassessment ofthein vivo proliferative historyof individual
candidate HSCs and progenitor cells over the course of several
weeks. A unique feature of this approach was that streptavidin-
based detection of the biotin probe allowed for preservation of cell
viability throughout analysis. Therefore, prospectively isolated
HSCs with different proliferation history could be subjected to
functional and molecular investigation. With this novel approach,
we could confirm previous studies demonstrating that functionally
defined HSCs are slow dividing compared to their down-stream
progenitor cell subsets [3,5], although long-term HSC dormancy
was, if present at all, a very rare phenomenon.
In our studies, a subset of cells within a candidate HSC
compartment was found to divide with slower kinetics and harbor
improved in vivo multi-lineage competitive repopulation and self-
renewal capacities in steady state. These slowly dividing HSCs
represented the most primitive subset of HSCs, and enhancement of
their proliferation kinetics in steady state, but not after cytostatic
stress, marked a primary event associated with loss of HSC self-
renewal.
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Tracing proliferation history of candidate hematopoietic
stem cells using an in vivo biotinylation strategy
Intravenous administration of esterized versions of biotin is a
well-established technique to label erythrocytes and platelets in vivo
[10,11]. The life span of such non-dividing cells can then be
determined by enumerating the fraction of label-retaining cells in
circulation at various time points after biotinylation. Importantly,
such labeling is characterized by remarkable stability, highlighted
by the ability to trace biotin-labeled erythrocytes more than 100
days after labeling [12]. We speculated that biotin labeling could
also be used to label other cell types. Of particular interest to us
was its labeling efficiency in mitotically competent cells.
Administration of biotin to mice resulted in complete labeling of
all hematopoietic cells in peripheral blood, spleen, bone marrow
(Fig. 1A), and thymus (JMN and DB, data not shown) as early as
five minutes post-injection. Serum taken immediately from biotin-
injected mice failed to label cells of untreated mice, demonstrating
the rapid clearance of biotin from circulation (Fig. 1A).
Shortly after intravenous biotin injection, the biotin label was
found to be highly uniform (Fig. 1A). By contrast, when investigated
several days after labeling, individual cells exhibited significant
differences in biotin label (Fig. 1B). We speculated that this
difference was caused by different cell cycle rates among individual
cells, such that biotin-labeled membrane proteins had been diluted
to a larger extent in more proliferative cells. In an attempt to verify
this hypothesis, we first labeled cells in vivo with biotin. Next, we
harvested biotin-labeled splenocytes from these mice and co-stained
them in vitro with the extensively utilized viable cell division tracking
dye CFSE [13]. Labeled cells were next reintroduced to new mice
and allowed to proliferate in vivo for 3 days, after which splenocytes
were again harvested and evaluated for their proliferative history
(Fig. 1C). In a complementary experiment CFSE labeled spleno-
cytes were obtained from OTII mice, whose peripheral T cells are
capable of antigen-dependent proliferation [14], and subjected to
immunization with Ovalbumin (Fig. S1) to track proliferative
history of CD4
+ T cells. These two experiments verified that the
biotin label was distributed to daughter cells with dilution kinetics
comparable to that of CFSE.
Next, we wanted to assess whether biotin labeling could be used
to track the in vivo proliferative behavior of HSCs. To this end, we
first biotin-labeled cells in vivo and prospectively FACS purified
HSCs from the bone marrow based on their unique cell surface
phenotype (experimental strategy outlined in Fig. 1D). One week
after biotin labeling, phenotypic HSCs were highly enriched
within the fraction of bone marrow cells with highest biotin
labeling (Fig. 1E). By contrast, less primitive progenitor cells had
diminished biotin labels (Fig. 1E).
To validate that the reduction in biotin label was due to
proliferation-induced dilution of the label in HSCs, we next
investigated how well the biotin dilution correlated with DNA
replication. For this purpose, mice receiving an intravenous
injection of biotin were simultaneously treated with BrdU for 7
days. Candidate HSCs were sorted by flow cytometry into fractions
withhigh and lowlevels of biotinlabelingand then stained forBrdU
content. Whereas cells with a diminishedbiotin label wereidentified
as being highly proliferative (8969% BrdU
+), cells with high levels
of biotin label had a reduced cell proliferation profile (1362%
BrdU
+) (Fig. 1F). In similar experiments that allowed comparison of
the BrdU and biotin techniques for proliferation analysis of
candidate HSC we observed significant changes in proliferation
rates as a consequence of high dose long term BrdU administration
(Fig. S2). These observations identify an important caveat with the
BrdU technique since it apparently modulates the proliferation rate
of candidate HSCs in vivo. We next investigated the ‘snapshot’ cell
cycle distributions of low- and high-biotin cells. This analysis
confirmed that a significant portion of both biotin-retaining and -
displacing cells were in a quiescent state at any given time, with less
than 20% in cycle (Fig. 1G). This agrees with previous data
demonstrating that the most primitive subset of cells in the HSC
population divides with prolonged kinetics [12]. However, whereas
the tracing of biotin labeling over time could easily establish
differences in proliferative activity between individual candidate
HSCs (Fig. 1E), these experiments highlight the need for large
variationsinmitoticindexinorderforsnapshotcell cycleanalysesto
adequately reveal the differential proliferative behavior of rare
subsets such as the candidate HSC fraction investigated here.
Heterogeneous proliferation kinetics within a candidate
HSC compartment
Previous studies have suggested that 50–60% of all HSCs divide
within 7 days, with an almost complete turnover of the HSC
compartment by 30 days [3,4]. Because HSCs analyzed in these
studies were defined by phenotype alone, heterogeneity in
proliferation kinetics could reflect either the presence of functionally
distinct HSC subsets or differences in regulation or maintenance of
quiescence in individual HSCs. We speculated that differential
proliferative properties within HSC-enriched populations could be
linked to changes in cellular function. To begin to address this
question, we first evaluated the in vitro clonogenic capacity of
candidate HSCs with differential proliferative histories during the
course of 7 days. These experiments did not reveal any major
differences associated with proliferative history (Fig. 2A). In order to
assay their in vivo HSC properties, slow and more rapidly
proliferating candidate HSCs were next competitively transplanted
into lethally irradiated congenic recipients, and HSC engraftment
was evaluated by their multi-lineage contribution to the peripheral
blood cell pool. These experiments revealed that the slowly dividing
HSC subset was superior at competitively reconstituting recipient
mice in the long-term (Fig. 2B) and displayed competence at
producing the full range of hematopoietic cell lineages (Fig. S3). A
similar relationship was observed for their self-renewal abilities, as
determined by serial transplantation of primary engrafted donor
cells (Fig. S3). When performing biotin chase for longer time
periods, we could establish complete turnoverof all candidateHSCs
within as little as three weeks (Fig. 2C), at which time no detectable
HSC activity was present within candidate HSC displaying biotin
intensities at original levels (Fig. 2D). These data demonstrate that
isolation and functional evaluation of cells based on their past
proliferation kinetics can be used to identify the most primitive
subset of cells within the HSC compartment, and that changes in
proliferative behavior to a large extent precede the changes in HSC
phenotype that accompany loss of HSC self-renewal.
Tracing the functional in vivo behavior of candidate HSCs
as a consequence of stress or divisional retardation
To examine HSC responses to biological stress, we next
investigated their in vivo proliferation following the administration
of the immunosuppressant cyclophosphamide (CY). Metabolites of
CY form DNA crosslinks that normally induce cell death.
However, toxic metabolites are not formed in HSCs and therefore
the main effect of CY on HSCs is on activation to compensate for
the loss of downstream progenitor cells [6]. Importantly, and in
contrast to many other chemotherapeutic agents, HSC from CY
treated mice retain their cell surface phenotype and functional
properties [15,16]. To study the effect of CY on HSC
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PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3710Figure 1. Non-invasive biotin labeling, a tool to separate cells with differential divisional kinetics. (A) Biotin label intensities on T cells
from blood, spleen and bone marrow 5 minutes after intra venous injection of biotin, or on peripheral blood T cells mixed with serum (serum control)
taken 15 minutes after intra venous injection of biotin (representative plots from one of 5 mice in each group). (B) Reduction of biotin label
intensities on CD4/CD8 thymocyte subsets 3 days after biotin injection (DN=double negative, DP=double positive, and SP=single positive cells).
Initial biotin intensities are indicated by non-dividing erythrocytes (representative plots from one of 10 mice in total). (C) Dilution kinetics of biotin in
relation to the intra-vital tracking dye CFSE. Splenocytes were labeled with biotin by intra venous injection, harvested and stained with CFSE in vitro
and subsequently transferred to sub-lethally irradiated recipients (n=7). Following 3 days of chase, reduction in label intensities of CD8
+CD44
+ T cells
were evaluated by FACS. (D) Experimental outline for labeling and analysis of bone marrow cells (BM) based on differential biotin label dilution. (E)
Prospective isolation of hematopoietic stem and progenitor cells and evaluation of biotin dilution kinetics 7 days following intra venous biotin
injection reveals augmented proliferation kinetics (biotin dilution) accompanying HSC differentiation (representative plots from one of more than 30
separate isolations). (F) BrdU label frequencies of LSKCD150
+ cells sorted as biotin low and high onto slides for BrdU staining 7 days after biotin
injection (images show differences in label intensities of representative biotin low and high BrdU positive cells). (G) Cell cycle status (determined by
Ki67/DAPI stain) of LSKCD150
+ HSCs with high and low biotin intensities 7 days after biotin injection (n=5). All data are presented as mean (6SD).
doi:10.1371/journal.pone.0003710.g001
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treatment (Fig. 3A) and investigated the biotin label on HSCs after
4 days of chase. Candidate HSCs from CY-treated mice
proliferated at a dramatically faster rate than candidate HSCs
from vehicle-treated mice (Fig. 3B). By contrast, candidate HSCs
from previously CY- and vehicle-treated mice displayed similar
proliferation levels when hematopoietic parameters had ap-
proached original levels 10 weeks after CY treatment (Fig. 3B,
Fig. S4). These experiments demonstrate that although cytostatic
administration profoundly affects the proliferation kinetics of
HSCs in the short-term, such effects are transient and therefore
reversible. We furthermore could conclude that the increased rates
of HSC proliferation in response to CY treatment leads to rapid
and complete turnover of the whole HSC population to ensure
hematopoietic recovery. Thus, we found no evidence for slow
proliferating HSCs with extraordinary abilities to remain quies-
cent in situations of extreme stress.
It is well established that the interactions of HSCs with the bone
marrow microenvironment can significantly influence their
function and fate [17]. Stromal-cell-derived factor 1 (SDF-1)
interacts with the CXC chemokine receptor 4 (CXCR4) on HSCs
to mediate their homing to the bone marrow HSC niche. It has
been proposed that one function of such niches is to mediate HSC
quiescence [17]. We therefore hypothesized that enhancement of
this interaction might increase HSC adherence to the bone
marrow HSC microenvironment, and perhaps contribute to the
maintenance of HSC quiescence. Sphingosine 1-phosphate
receptors (S1PR) affect the responsiveness of HSCs and progenitor
cells to chemokines, including SDF-1, resulting in enhanced
homing to the bone marrow following transplantation, as well as
increased adherence to stromal cells [18]. FTY720 is an
immunosuppressant isolated from the ascomycete Isaria sinclairii.
It has previously been demonstrated to act as a ligand for S1P
receptors to induce homing and retention of circulating lympho-
cytes to lymph nodes [19]. Activation of S1PR on HSCs by
repeated intra-peritoneal injection of FTY720 resulted in en-
hanced SDF-1 signaling in HSCs, but had no immediate effect on
levels of HSC and progenitor cells in the bone marrow (Fig. 3A,
C). However, comparison of the in vivo proliferation kinetics in
FTY720-treated mice revealed that candidate HSCs had retarded
proliferation kinetics when compared to vehicle-treated controls
(Fig. 3D). To evaluate whether such changes could result in
increased functional HSC activity, lethally irradiated mice were
competitively transplanted with high- or low-biotin candidate
HSC isolated from FTY720 or vehicle-treated mice. These
experiments revealed that S1PR activation on candidate HSCs,
which appears to induce such cells into a more quiescent state, is
not sufficient to enhance HSC function (Fig. 3E). Therefore, S1PR
activation appears to retard the proliferation of primitive
progenitors, rather than long-term repopulating HSCs.
Alterations in divisional kinetics mark an initial event in
HSC commitment
Having established a reliable assay to track in vivo cellular
proliferation history, we next decided, as a proof-of-principle, to
conduct analyses of the gene expression patterns associated with
proliferation of candidate HSCs. Following biotin injection and 7
days of chase, candidate HSCs with high or low biotin retention
were isolated by flow cytometry. Next, mRNA was extracted and
subjected to hybridization onto Affymetrix whole genome
oligonucleotide arrays. Following stringent selection criteria, these
experiments revealed 156 genes (165 probe sets) to be two-fold or
higher differentially expressed (Fig. 4A, Table S1), with 134 genes
(142 probe sets) up-regulated upon proliferation, and 22 genes (23
probe sets) associated with quiescence/slow proliferation. Gene
Ontology analysis revealed that as much as 31% of the genes up-
regulated in the highly proliferating fraction were associated with
cell cycle (p-value 1.86610
211), and therefore recognized the
cellular process underlying the differential label-retention over
time using an independent and unbiased approach. With a few
exceptions, most of the genes identified by this approach have not
been previously investigated regarding their involvement in HSC
Figure 2. Biotin dilution kinetics reveals functional heteroge-
neity within HSC populations in vivo. (A) Single cell in vitro
clonogenic potential (n=4 separate experiments) of LSKCD150
+ HSCs
with differential proliferation history and (B) long-term peripheral blood
cell reconstitution from competitive transplantations of 5 isolated
LSKCD150
+ HSCs following 7 days chase. Cells with fast (biotin
low)o r
slow (biotin
high) proliferation kinetics were compared (n=7 recipients
per group, data from one of three independent experiments). Numbers
on x-axis represents weeks post transplantation. Similar differences
were found within HSCs populations isolated using different sets of
phenotypic markers including CD34 [27] and CD48 [28]. (C) Biotin
dilution kinetics on LSKCD150
+ HSC evaluated by FACS at several time
points following intravenous injection of biotin. At all time points, the
biotin intensity of non-dividing Ter119
+ erythrocytes in the bone
marrow was sustained at original levels (n=5–7 mice per data point).
(D) Biotin label intensities on LSKCD150
+ HSCs after 21 days chase and
total donor reconstitution frequencies from competitive transplanta-
tions of 5 biotin low (blue), intermediate (red), and high (green) HSCs
(n=4–6 recipients/group). Numbers on x-axis represents weeks post
transplantation. All data are presented as mean (6SD).
doi:10.1371/journal.pone.0003710.g002
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from HSCs and their immediate progeny, we identified several
common genes. Onset of CD48 expression (Fig. 4B) in HSCs has
been shown to mark an early step in their commitment towards a
progenitor cell stage, along with loss of stem cell properties [20].
Furthermore, and in line with previous studies, genes such as
Vcam1 and Necdin, which are associated with long-term HSC
identity [21], were expressed at higher levels in the more slowly
dividing fraction. Based on these experiments, we conclude that in
vivo proliferative history should be a useful marker to unravel the
initial molecular differentiation events of HSCs and to identify
putative novel regulators of HSC quiescence.
Discussion
The mechanisms underlying the fates of HSCs are still largely
unknown, although several descriptive models of such processes
have been established. Common among these is that self-renewing
and multi-potent long-term HSCs exist throughout life, maintain-
ing quiescence relative to other hematopoietic cells [1]. HSC
progeny irreversibly become more rapidly proliferating multi-
potent progenitors, with an ability to contribute to multilineage
hematopoiesis for no longer than 6 to 8 weeks [1]. The regulators
of the cell cycle processes that underlie this scheme of
differentiation remain to be determined. In doing so, there is a
need for robust techniques to study cell proliferation kinetics in vivo.
Previous attempts to investigate HSC proliferation history have
been limited to assays that involve in vitro manipulation of donor
cell populations for efficient labeling, or that require fixation to
permit experimental readout [2,3,5,8,22]. Therefore, most existing
experimental data for HSC quiescence has been correlative,
resting on the phenotypic identity of HSCs rather than their
functional capacities. Here, we developed an in vivo labeling
technique adapted to permit assessment of cellular proliferation
history while leaving blood cell homeostasis unperturbed. We
believe this is key, because although prospective identification of
stem cells has advanced considerably during the last decades, with
the hematopoietic system representing the forefront of such work,
functionality still remains the only reliable criterion by which to
define stem cell identity [1]. Furthermore, this approach offers the
Figure 3. Tracing the functional in vivo behavior of candidate HSCs as a consequence of stress or divisional retardation. (A)
Experimental outline for evaluation of Cyclophosphamide (CY) and FTY720 effects on HSC proliferation. (B) Biotin intensities following vehicle
(control) or CY injections (n=7 mice per group and time point). (C) Bone marrow cell parameters measured by a microcell counter (left), and stem cell
frequencies measured by FACS (right), three days post FTY720 injections (n=4 mice). (D) Proliferation kinetics of LSKCD150
+ HSCs was significantly
retarded by FTY720 treatment, evaluated by measuring biotin intensities three days following vehicle (control) or FTY720 injections (n=7 mice per
group, p-value=1.18610
25). (E) Fold difference in total donor reconstitution frequencies from competitive transplantations of 50 high- or low-biotin
LSKCD150
+ HSCs in one representative experiment of two (n=10 mice per group). All data are presented as mean (6SD).
doi:10.1371/journal.pone.0003710.g003
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with more extensive proliferation. Because injection of biotin
labels hematopoietic cells throughout the hematopoietic compart-
ments, we anticipate that this technique should be useful in several
other contexts where in vivo proliferation of hematopoietic cells is
to be monitored.
There are potential caveats to this proposed technique.
Compared to in vitro labeling approaches with compounds such
as CFSE, the in vivo biotin technique does not yield similarly
intense staining patterns. This means that the number of cell
divisions that can be traced over time become more limited,
although it still provide sufficient resolution for the work presented
here. Furthermore, as the technique rests on the labeling of
membrane proteins that segregate to daughter cells upon division,
it is conceivable that some non–proliferation-associated dilution of
the biotin label may occur as biotin-labeled membrane proteins
with high turnover are exchanged or internalized. Similar
concerns apply to established in vitro labeling reagents such as
CFSE [23], although we believe it should not greatly affect
experimental interpretation, particularly when evaluated in a
comparative setting. However, this issue may be of concern when
attempting to determine more accurately the number of cell
divisions that individual cells have undergone during a defined
time frame. Perhaps one way to obtain such information is to use
non-dividing erythrocytes to define the biotin label associated with
undivided cells. This population is present in all bone marrow
preparations of mice receiving biotin, and can therefore be used as
an internal standard to determine the biotin label dilution in
individual mice. Using commercial software for flow cytometric
analysis, enumeration of cell division history can next be
performed to model proliferation. One example of such an
analytic strategy is provided in Fig. 5. Here, we evaluated the in
vivo proliferative history of candidate common lymphoid precursor
(CLP) cells in young and aged mice during one week. In vitro
evaluation has previously demonstrated that aged CLPs are
characterized by poor mitogenic responsiveness [24]. Using the
strategies outlined herein, such analyses can now be easily
extended to a more physiologic in vivo setting.
With the described biotin labeling approach, we have found
that the vast majority of candidate HSCs regularly enters the cell
cycle, albeit with slower kinetics compared to other hematopoietic
progenitors. The nature of this quiescence is relative rather than
absolute, because we could find no evidence that HSCs lie
dormant for extended time periods. Furthermore, proliferation
kinetics was found to be a highly useful parameter with which to
assess differences in cellular function of individual cells within a
highly purified HSC subset (LSKCD150
+; constituting only
,0.01% of total bone marrow cells). We speculated that the in
vivo modulation of HSC proliferation kinetics, either by CY or
FTY720 administration, would affect HSC function. However, we
could observe neither enhancement nor loss of HSC function
despite enforced cell cycling or retention, and so we currently
interpret changes in HSC proliferation in steady state as secondary
effects attributable to the differentiation process, and not the
initiator of commitment. Regardless, these approaches demon-
strate the utility of the in vivo biotin labeling assay in revealing the
Figure 4. Gene expression profiling of HSCs with different
proliferative kinetics, based on biotin dilution. (A) Heat map
showing differential expression profiles of LSKCD150
+ HSCs isolated as
fast (biotin low) or slow (biotin high) proliferating based on differential
biotin intensity 7 days after in vivo biotin labeling. Up-regulated genes
are shown in red and down-regulated genes in green. A and B refer to
biological replicates. (B) FACS analysis of CD48 protein levels (%) on
LSKFlt3
2CD150
+ candidate HSCs in relationship to their proliferation
history.
doi:10.1371/journal.pone.0003710.g004
Figure 5. Aged common lymphoid precursors exhibit a diminished proliferative capacity in vivo. Young (10–12 week) and aged (100
week) mice were injected with biotin. Bone marrow was harvested 7 days later, and analyzed for cells with a common lymphoid precursor (CLP)
phenotype [29] in addition to biotin label determination. (A) Biotin label profiles of erythrocytes (non-dividing control) and CLPs, as well as the biotin
label profile of CLPs in the absence of biotin injection. (B) The biotin profiles of dividing and non-dividing erythrocytes were used to model individual
cell divisions using the ‘Proliferation’ function in FlowJo software. (C) Young and aged CLPs were evaluated for the number of cell divisions they had
undergone during 7 days using the modeling strategy described in (B). All data are presented as means (6SD); n=5 mice per group.
doi:10.1371/journal.pone.0003710.g005
Proliferation Affects HSC Fate
PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3710proliferative effects of externally administered compounds that
modulate in vivo proliferation dynamics.
Until now, it has remained uncertain as to whether a small
fraction of cells within the HSC pool remain mitotically quiescent
for extended periods of time. We have determined here that more
than 90% of all HSCs divide within 10 days, with complete HSC
turnover taking place within a three-week window. Therefore, we
may conclude that label retention is not a property that uniquely
defines cells with HSC properties. These observations raise
questions as to whether differences in proliferative rates of HSCs
and committed progenitor cells are sufficient to keep HSCs
protected from exhaustion and accumulation of cellular and
genetic damage throughout development.
In summary, we have developed an assay that for the first time
allows for the direct demonstration that slowly dividing candidate
HSCs in steady state have an improved in vivomulti-lineage and self-
renewing capacity compared to their more rapidly proliferating
counterpart. The prolonged cell divisional kinetics associated with
HSCs appears to mark a defining HSC property, likely to be
associated with their maintenance and self-renewal throughout life.
Materials and Methods
Mice and pre-treatment
Congenic C57BL/6 strains differing at the CD45 locus were
used in all experiments. Experiments were approved by the ethical
committee at Lund University. Mice were housed under
pathogen-free conditions in individually ventilated cages. NHS-
biotin (EZ-Link Sulfo-NHS-LC-LC-biotin; Pierce) was injected
intravenously at 5 mg/ml in 0.9% saline (0.2 ml/mouse). FTY720
(Cayman Chemical) was reconstituted in DMSO (20 mg/ml) and
aliquots were diluted for injection with 0.9% saline (0.25 mg/ml)
at each injection time, and 0.1 ml/mouse was injected intrave-
nously at three time points every second day (at the last injection
time, mice were in addition injected intravenously with biotin).
Cyclophosphamide (Sendoxan; Baxter) was injected intravenously
(0.1 ml/mouse of 25 mg/ml in 0.9% saline) twice, with injections
two days apart. Measurements of peripheral blood and bone
marrow parameters were performed using a microcell counter
(Sysmex).
HSC purification
Isolation of candidate HSCs from the bone marrow of 10-14
weeks old C57BL/6 mice was performed as described previously
[25], using a FACSAria (Becton Dickinson). Briefly, isolated bone
marrow cells were enriched for c-kit positive cells by c-kit
antibody-conjugated beads (Miltenyi) and magnetic depletion of
c-kit negative cells. Enriched cells were stained with fluorochrome-
conjugated antibodies specific for lineage markers (B220, CD3,
Gr-1, Mac-1, Ter119), CD48, c-kit, Sca-1, CD34, Flt3, and
CD150 and streptavidin for detection of in vivo labeled biotin. Re-
analysis of sorted cells reproducibly demonstrated high purity
(.98%).
BrdU retention and cell cycle analysis
Mice were given an intraperitoneal injection of BrdU (Sigma-
Aldrich) in 0.9% saline (1 mg per 6 g body weight), and drinking
water containing BrdU (1 mg/ml). Seven days later, HSCs were
sorted on a FACSAria using a modulated specimen holder for
simultaneous 4-population sort directly onto poly-lysine coatedglass
slides. Following fixation and denaturation, BrdU was detected by
biotinylated monoclonal antibodies (PRB-1) and ABC/DAB
(Vector Laboratories). For evaluation of the effect from accumula-
tionof BrdU on proliferation behavior of HSCs high dose treatment
with BrdU was continued for 10 days (daily intraperitoneal
injections of 1 mg BrdU per 6 g body weight). For cell cycle
analysis, bone marrow cells were incubated with fluorophore-
conjugated antibodies as described above, fixed (2% paraformal-
dehyde, 20 min),stained with Ki67 antibodies (in0.1% saponin,1h)
and DAPI. All samples were analyzed on a FACSAria.
CFSE label dilution
Comparison of CFSE and biotin label dilution kinetics was
performed on T cells in spleens. Donor splenocytes (CD45.1) were
labeled with biotin in vivo by intra venous injection and directly
thereafter isolated and stained in vitro with CFSE (0.5 mM in PBS
at room temperature for 5 minutes). After blocking with PBS
supplemented with 5% FCS, 7610
6 splenocytes were intra
venously transplanted into recipient (CD45.2) mice. After 3 days,
the two types of labels were compared on donor derived
CD8
+CD44
+ T cells in recipient spleens by FACS. Alternatively,
splenocytes were obtained from CD45.1/CD45.2 OTII mice [14],
CFSE stained and next transferred to CD45.2 hosts. 5 minutes
post-transfer of cells, hosts were injected with biotin. The following
day, mice were immunized with Ovalbumin and adjuvant, and
proliferation kinetics of CD4
+ donor derived T cells was evaluated
3 days after immunization. All samples were analyzed on a
FACSAria.
Single cell cultures
HSCs were sorted using a FACSAria (1 cell/well, 120 cells/
group) in Terasaki plates (Nunc) and cultured in conditions as
previously described [23]. Each well was inspected within six hours
of sorting, and only wells containing one cell were included in the
experiment. Wells were scored for cell growth after 10 days of
culture at 37uC.
Competitive repopulation assays
FACS-sorted HSCs from C57BL/6 mice (CD45.1) were
transplanted (5–50 cells per mouse) into lethally irradiated (900
rads) congenic recipients (CD45.2) together with 200,000
unfractionated bone marrow competitor cells (CD45.2) to allow
quantification of reconstitution activity and ensure survival of
lethally irradiated mice. Hematopoietic donor cell reconstitution
and lineage distribution was evaluated in peripheral blood at
different time points post-transplantation by FACS, as previously
described [25]. For secondary transplantations, lethally irradiated
recipient mice were competitively transplanted with 50
LSKCD150
+ HSCs isolated from primary recipients.
Affymetrix gene expression analysis and quantitative RT-
PCR
RNA was extracted from 2,000–3,000 HSCs sorted as high- or
low-biotin with an RNeasy mRNA purification kit (Qiagen).
Subsequent handling was performed by the SweGene Affymetrix
unit at Lund University as previously described [26]. Probe level
expression values were extracted by RMA, and analysis was
performed with dChip software (http:/biosun1.harvard.edu./
complab/dchip/) after filtering (0.5,SD/mean,1,000 and a
baseline expression of at least 50 in 50% of samples). Genes with
two-fold or higher expression differences were identified (at 90%
or higher confidence interval).
Statistics
All data are reported as mean6SD. Statistical comparisons
were made using Student’s t-test for unpaired samples and
differences with P,0.05 were regarded as significant.
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Figure S1 CFSE and biotin label intensities are similarly
reduced following cell division. (A) 5610
6 splenocytes from
CD45.1/CD45.2 OTII donor mice were stained with CFSE in
vitro and thereafter transplanted to CD45.2 recipients. Donor and
recipient cells were labeled with biotin in vivo 5 minutes post cell
transfer, and label dilutions were analyzed on donor CD4
+ T cells
3 days following immunization with Ovalbumin. (B–C) Represen-
tative plots of CFSE and biotin label dilution on T cells in recipient
spleens (n=3).
Found at: doi:10.1371/journal.pone.0003710.s001 (0.85 MB TIF)
Figure S2 Effect on proliferation of candidate HSC following
BrdU treatment in vivo. (A) Mice received intra peritoneal
injections with BrdU or PBS for 10 days prior to analysis. On
day 3 after start of BrdU injections, biotin was injected
intravenously. The proliferation effect from BrdU accumulation
in LSKCD150
+CD34
2 HSCs was determined by FACS analysis
of biotin intensities. (B) Using the ’Proliferation’ function in FlowJo
software, the biotin profile of erythrocytes (non-dividing cells) was
used to model the number of cell divisions that individual
LSKCD150
+CD34
2 HSCs had undergone in either PBS injected
or BrdU injected mice. Graphs depicts % of HSCs (y-axis) having
undergone the defined number of cell divisions (y-axis). Black bars
show HSCs proliferation in PBS treated mice and grey bars show
HSC proliferation in BrdU treated mice. All data are presented as
means (6SD); n=5 mice per group. Asterisks indicate p-values
lower than 0.05.
Found at: doi:10.1371/journal.pone.0003710.s002 (0.94 MB TIF)
Figure S3 Biotin dilution kinetics reveals heterogeneity of self-
renewing properties and multi-potency in HSC populations in vivo.
(A) Sort gates for isolation of LSKCD150
+ HSC from mice 7 days
after intra venous biotin injection (left panel). Re-analysis of fast
(biotin low) and slow (biotin low) proliferating HSCs based on
differential distribution of biotin intensities (right panel). Brackets
in left panel represents intensity of non-injected negative control
LSKCD150
+ HSCs (left brackets) and positive control
LSKCD150
+ HSCs isolated five minutes after biotin injection
(right brackets). (B) Total donor peripheral blood reconstitution
frequencies in primary recipients after competitive transplanta-
tions of 50 biotin high or low LSKCD150
+ HSCs isolated after 7
days chase. Secondary recipients were competitively transplanted
with 50 LSKCD150
+ HSCs isolated from primary recipients.
Numbers on x-axis represents weeks post transplantation. Data are
from one representative experiment of five (45 mice in each group
in total). (C) Distribution of total donor reconstituting cells from
competitive transplantations of 50 biotin high or low LSKCD150
+
cells into B cells (B220
+), T cells (CD4
+ and/or CD8
+) and myeloid
cells (CD11b
+). Numbers on x-axis represents weeks post
transplantation. Data are from the same experiment as in (B)
and are presented as mean (6SD).
Found at: doi:10.1371/journal.pone.0003710.s003 (2.67 MB TIF)
Figure S4 Hematopoietic parameters following Cyclophospha-
mide (CY) treatment (A) Total bone marrow cells measured by a
microcell counter (left), and candidate HSC frequencies measured
by FACS (right), one week after CY injections. (B) Body weight
and peripheral blood cell levels over time in vehicle (control) and
CY-injected mice. Numbers on x-axis represents weeks post CY
injections. Asterisks represent significant differences compared to
respective control group (n=7 mice per group and time point). All
data are presented as mean (6SD).
Found at: doi:10.1371/journal.pone.0003710.s004 (0.52 MB TIF)
Table S1 Genes and probe sets differentially expressed in
LSKCD150
+ HSC isolated as fast proliferating (biotin low) or
slow proliferating (biotin high).
Found at: doi:10.1371/journal.pone.0003710.s005 (0.02 MB
PDF)
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